Trial Profile

Acute STEMI Treated With Primary Angioplasty and Intravenous 0.5 mg/kg Lovenox or UFH to Lower Ischemic and Bleeding Events.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enoxaparin sodium (Primary) ; Enoxaparin sodium (Primary) ; Heparin; Heparin
Indications Embolism and thrombosis; Myocardial infarction
Focus Biomarker; Therapeutic Use
Acronyms ATOLL

Most Recent Events

25 Aug 2018 Results (n=129) published in the American Journal of Cardiovascular Drugs
03 Jul 2015 Results published in the American Heart Journal.
04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com